Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Dec 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety of giving radiation therapy alongside new treatments for breast cancer. Radiation therapy is an important part of breast cancer treatment, and there are also newer medications that have shown to be effective. The goal of this trial is to find out if it is safe for patients to receive both radiation and these new therapies at the same time, as some earlier research suggests that they may work better together.

To participate in the trial, individuals must be between 18 and 70 years old and have a confirmed diagnosis of breast cancer that requires radiation treatment. They should also need one of the newer therapies, such as capecitabine or HER2 inhibitors. Participants will receive both radiation and their assigned medication during the study and will be closely monitored for safety. This research could provide valuable information that helps doctors make better treatment decisions for breast cancer in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall/breast with or without lymph node regions.
• • Need to receive one of the following therapies according to guidelines, capetabine, CDK4/6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.
• Exclusion Criteria:
• • Male breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and/or after radiotherapy. With severe other disease.